Progression of liver fibrosis in HIV/HCV genotype 1 co-infected patients is related to the T allele of the rs12979860 polymorphism of the IL28B gene

European Journal of Medical Research

Volumn 16, Issue 8, 2011, Pages 335-341

  Lutz, P ^a   Wasmuth, J C ^a   Nischalke, H D ^a   Vidovic, N ^a   Grunhage F ^a,b   Lammert, F ^b   Oldenburg, J ^a   Rockstroh, J K ^a   Sauerbruch, T ^a   Spengler, Ulrich ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

HCV; HIV; IL28B; Liver fibrosis; Polymorphism; Transient elastography

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; INTERLEUKIN 28B;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; FEMALE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PROTEIN POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE; TREATMENT RESPONSE; ASPARTATE AMINOTRANSFERASE TO PLATELET RATIO INDEX; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DIGESTIVE SYSTEM DISEASE ASSESSMENT; ELASTOGRAPHY; FIB 4 SCORE; FOLLOW UP; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HEMATOLOGICAL PARAMETERS; HEMOPHILIA; HEPATITIS C VIRUS GENOTYPE 1; HEPATOBILIARY PARAMETERS; LIVER STIFFNESS; LL28B GENE; LONGITUDINAL STUDY; REAL TIME POLYMERASE CHAIN REACTION; TRANSIENT ELASTOGRAPHY;

ADULT; AGED; ALLELES; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; ELASTICITY IMAGING TECHNIQUES; FEMALE; FIBROSIS; GENOTYPE; HEPACIVIRUS; HIV; HIV INFECTIONS; HUMANS; INTERLEUKINS; LIVER DISEASES; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 80052213149     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Bühler S, Söllner J, Seybold U, Bogner JR. [Causes of death in HIV patients]. MMW Fortschr Med. 2009 Apr 30;151(18):56-57.
2. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, Snydman DR. Increasing mortality due to endstage live disease in patients which human immuno-deficiency Virus infection. Clin Infect Dis. 2001 Feb 1;32(3):492-7. (Pubitemid 32173638)
3. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H Jr, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT; APRICOT Study Group. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004 Jul 29;351(5):438-50 (Pubitemid 38988593)
4. Macías J, Berenguer J, Japón MA, Girón JA, Rivero A, López-Cortés LF, Moreno A, González-Serrano M, Iribarren JA, Ortega E, Miralles P, Mira JA, Pineda JA. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology. 2009 Oct;50(4):1056-63
5. Sulkowski MS, Mehta SH, Torbenson MS, Higgins Y, Brinkley SC, de Oca RM, Moore RD, Afdhal NH, Thomas DL. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS. 2007 Oct 18;21(16):2209-16. (Pubitemid 350287219)
6. Bräu N, Salvatore M, Ríos-Bedoya CF, Fernández-Carbia A, Paronetto F, Rodríguez-Orengo JF, Rodríguez-Torres M. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. Hepatol. 2006 Jan;44(1):47-55. (Pubitemid 41772515)
7. Souza AR, Tovo CV, Mattos AA, Chaves S. There is no difference in hepatic fibrosis rates of patients infected with hepatitis C virus and those co-infected with HIV. Braz J Med Biol Res. 2008 Mar;41(3):223-8. (Pubitemid 351761076)
8. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009 Oct 8;461(7265):798-801.
9. Fabris C, Falleti E, Cussigh A, Bitetto D, Fontanini E, Bignulin S, Cmet S, Fornasiere E, Fumolo E, Fangazio S, Cerutti A, Minisini R, Pirisi M, Toniutto P. IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: Role in the course of chronic viral hepatitis and the development of HCC. J Hepatol. 2010 Sep 19. [Epub ahead of print]
10. Bedossa P, Dargere D, Paradis V. Sampling variabilitiy of liver fibrosis in chronic hepatitis C. Hepatology. 2003 Dec;38(6):1449-57. (Pubitemid 37466971)
11. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008 May;48(5):835-47
12. Sánchez-Conde M, Montes-Ramírez ML, Miralles P, Alvarez JM, Bellón JM, Ramírez M, Arribas JR, Gutiérrez I, López JC, Cosín J, Alvarez E, González J, Berenguer J. Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markers. J Viral Hepat. 2010 Apr;17(4):280-6.
13. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok A. A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis C. Hepatology. 2003 Aug;38(2):518-26.
14. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M; APRICOT Clinical Investigators. Development of a Simple Noninvasive Index to Predict Significant Fibrosis in Patients With HIV/HCV Coinfection. Hepatology. 2006 Jun;43(6): 1317-25. (Pubitemid 43980111)
15. Grünhage F, Wasmuth JC, Herkenrath S, Vidovic N, Goldmann G, Rockstroh J, Lammert F, Oldenburg J, Sauerbruch T, Spengler U. Transient elastography discloses identical distribution of liver fibrosis in chronic hepatitis C between HIV-negative and HIV-positive patients on HAART. Eur J Med Res. 2010 Apr 8;15(4):139-44.
16. Vidovic N, Lochowsky RS, Goldmann G, Rockstroh J, Wasmuth JC, Spengler U, Sauerbruch T, Lammert F, Oldenburg J, Grünhage F. Correlation of transient elastography with APRI and FIB-4 in a cohort of patients with congenital bleeding disorders and HCV or HIV/HCV coinfection. Haemophilia. 2010 Sep 1;16(5): 778-85.
17. Nattermann J, Vogel M, Berg T, Danta M, Axel B, Mayr C, Bruno R, Tural C, Klausen G, Clotet B, Lutz T, Grünhage F, Rausch M, Nischalke HD, Schewe K, Bienek B, Haerter G, Sauerbruch T, Rockstroh JK, Spengler U; Kompetenznetz HIV/AIDS. Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients. Hepatology. 2007 Oct;46(4):1016-25.
18. Hou W, Wang X, Ye L, Zhou L, Yang ZQ, Riedel E, Ho WZ. Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages. J Virol. 2009 Apr;83(8):3834-42.
19. Langhans B, Kupfer B, Braunschweiger I, Arndt S, Schulte W, Nischalke HD, Nattermann J, Oldenburg J, Sauerbruch T, Spengler U. Interferon-lambda serum levels in hepatitis C. J Hepatol. 2010 Oct 23. [Epub ahead of print]
20. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009 Sep 17;461(7262):399-401.
21. Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, Shianna KV, Mottola L, Petruzzellis D, Bacca D, Carretta V, Minerva N, Goldstein DB, McHutchison JG. Interleukin -28B polymorphism determines treatment response of patients with hepatitis C genotype 2 or 3 who do not achieve a rapid virologic response. Gastroenterology. 2010 Sep;139(3):821-7, 827.e1.
22. McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, Patel K, Tillmann HL, Muir AJ, McHutchison JG. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology. 2010 Jun;138(7):2307-14.
23. Ralló NI, Naggie S, Benito JM, Medrano J, Restrepo C, Goldstein D, Shianna KV, Vispo E, Thompson A, McHutchison J, Soriano V. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS. 2010 May 15;24(8):F23-9.
24. Pineda JA, Caruz A, Rivero A, Neukam K, Salas I, Camacho A, Palomares JC, Mira JA, Martínez A, Roldán C, de la Torre J, Macías J. Prediction of Response to Pegylated Interferon plus Ribavirin by IL28B Gene Variation in Patients Coinfected With HIV and Hepatitis C Virus. Clin Infect Dis. 2010 Oct 1;51(7):788-95.
25. Montes-Cano MA, García-Lozano JR, Abad-Molina C, Romero-Gómez M, Barroso N, Aguilar-Reina J, Núñez- Roldán A, González-Escribano MF. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology. 2010 Jul;52(1):33-7.26.
26. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, Hong L, McKenzie A, Patel K, Shianna KV, McHutchison JG, Goldstein DB, Afdhal N. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology. 2010 Dec;52(6):1888-96.
27. Dill MT, Duong FH, Vogt JE, Bibert S, Bochud PY, Terracciano L, Papassotiropoulos A, Roth V, Heim MH. Interferon-Induced Gene Expression Is a Stronger Predictor of Treatment Response than IL28B Genotype in Patients with Hepatitis C. Gastroenterology. 2010 Nov 24. [Epub ahead of print]
28. Chen L, Borozan I, Sun J, Guindi M, Fischer S, Feld J, Anand N, Heathcote J, Edwards AM, McGilvray ID. Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection. Gastroenterology. 2010 Mar;138(3):1123-33.e1-3.
29. Wasmuth HE, Lammert F, Zaldivar MM, Weiskirchen R, Hellerbrand C, Scholten D, Berres ML, Zimmermann H, Streetz KL, Tacke F, Hillebrandt S, Schmitz P, Keppeler H, Berg T, Dahl E, Gassler N, Friedman SL, Trautwein C. Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology. 2009 Jul;137(1):309-19, 319.e1-3.
30. Ingiliz P, Chhay KP, Munteanu M, Lebray P, Ngo Y, Roulot D, Benhamou Y, Thabut D, Ratziu V, Poynard T. Applicability and variability of liver stiffness measurements according to probe position. World J Gastroenterol. 2009 Jul 21;15(27):3398-404.
31. Fraquelli M, Rigamonti C, Casazza G, Conte D, Donato MF, Ronchi G, Colombo M. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut. 2007 Jul;56(7):968-73. (Pubitemid 46999083)
32. Roulot D, Czernichow S, Le Clésiau H, Costes JL, Vergnaud AC, Beaugrand M. Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol. 2008 Apr;48(4):606-13.
33. Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: A meta-analysis of the risk factors. Hepatology 2010; 52: 71-78.
34. Vispo E, Barreiro P, Del Valle J, Maida I, de Ledinghen V, Quereda C, Moreno A, Macías J, Castera L, Pineda JA, Soriano V. Overestimation of liver fibrosis staging using transient elastography in patients with chronic hepatitis C and significant liver inflammation. Antivir Ther. 2009; 14(2):187-93.
35. Qurishi N, Kreuzberg C, Lüchters G, Effenberger W, Kupfer B, Sauerbruch T, Rockstroh JK, Spengler U. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet. 2003 Nov 22;362(9397):1708-13. (Pubitemid 37468321)
36. Pineda JA, García-García JA, Aguilar-Guisado M, Ríos-Villegas MJ, Ruiz-Morales J, Rivero A, del Valle J, Luque R, Rodríguez-Baño J, González-Serrano M, Camacho A, Macías J, Grilo I, Gómez-Mateos JM; Grupo para el Estudio de las Hepatitis Víricas de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI). Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology. 2007 Sep;46(3):622-30.